Posted by Michael Wonder on 19 Sep 2024
Glycomine receives FDA fast track designation for GLM101 for the treatment of PMM2-CDG
18 September 2024 - Glycomine announced today that the US FDA has granted fast track designation for GLM101, a mannose-1-phosphate replacement therapy in development for the treatment of patients with phosphomannomutase 2-congenital disorder of glycosylation.
GLM101 is a mannose-1-phosphate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation, previously known as CDG Type Ia.
